Onyx Biotec, a company in the Pharmaceuticals industry, reported revenue of ₹43 crore and net profit of ₹0.94 crore for the September 2026 quarter.
Onyx Biotec (NSE: ONYX-SM) closed at ₹39.45 on 20 Nov 2026, up 2.5% over the past year. Its market capitalisation is ₹72 crore.
Incorporated in 2005, Onyx Biotech Ltd manufactures and sells Sterile Water for Injections, Dry Powder Injections and Dry Syrup for India and overseas, through a B2B business model
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.